Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.

ABSTRACT:

Background

While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable, predictors of efficacy. Body composition phenotypes may reflect aspects of patients' immunology and thereby their ability to respond to ICIs. This study aims to explore the possible association between pre-treatment body composition phenotypes, tumour response, and clinical outcomes in patients receiving first-line pembrolizumab monotherapy for advanced NSCLC.

Methods

A retrospective review of consecutive patients with treatment-naïve NSCLC and PD-L1 expression ≥

SUBMITTER: Trestini I 

PROVIDER: S-EPMC11634481 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature